Updates are available Correction dated 2021-11-26
Click to view Correction: https://doi.org/10.1186/s40478-021-01292-6
-
Authors
Russo, Marco J. http://orcid.org/0000-0001-8064-6685
Orru, Christina D.
Concha-Marambio, Luis
Giaisi, Simone
Groveman, Bradley R.
Farris, Carly M.
Holguin, Bret
Hughson, Andrew G.
LaFontant, David-Erick
Caspell-Garcia, Chelsea
Coffey, Christopher S.
Mollon, Jennifer
Hutten, Samantha J.
Merchant, Kalpana
Heym, Roland G.
Soto, Claudio
Caughey, Byron
Kang, Un Jung
-
Funding
Funding for this research was provided by:
National Institutes of Health (T32AG052909, R01 AG055053)
Michael J. Fox Foundation for Parkinson's Research (16712)
Division of Intramural Research, National Institute of Allergy and Infectious Diseases
International Parkinson and Movement Disorder Society
- License Information
-
More Information
Article History
Received: 9 August 2021
Accepted: 22 October 2021
First Online: 6 November 2021
Change Date: 26 November 2021
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1186/s40478-021-01292-6
Declarations
:
: All cerebrospinal fluid (CSF) samples and clinical data were collected according to the Parkinson’s Progression Markers Initiative (PPMI) study protocol. The PPMI research protocol and study documents are openly available at ExternalRef removed.
: Not applicable.
: MJR declares no competing interests. CS is Founder, Chief Scientific Officer, Consultant, shareholder and member of the Board of Directors of Amprion Inc, a biotech company focusing on the commercialization of SAA technology for diagnosis of Parkinson’s disease and related synucleinopathies. UJK is on the Scientific Advisory Board of Amprion, Inc. CS, LCM, CMF, BH are inventors on several patents related to the SAA (PMCA) technology and are affiliated to Amprion Inc. CDO, AGH, BRG and BC have a patent Provisional (US): 62/567,079 pending, a patent PCT: PCT/US2018/052968 pending, a patent Canada: 3074914 pending, a patent Europe: 18786583.7 pending, and a patent U.S.: 16/652,804 pending. SG, RGH, and JM are employees of AbbVie. DEL declares no competing interests. CCG declares no competing interests.
